康辰药业(603590.SH)：KC1036治疗晚期胸腺癌的关键性Ⅲ期临床研究获得CDE批准

智通财经03-18

智通财经APP讯，康辰药业(603590.SH)发布公告，公司自主研发的KC1036片(简称“KC1036”)获得国家药品监督管理局药品审评中心(以下简称“CDE”)批准开展“评估KC1036对比研究者选择的化疗单药治疗既往至少一线含铂化疗失败的晚期复发或转移性胸腺癌的随机、开放、多中心Ⅲ期临床研究”。KC1036是公司自主研发的化学药品1类创新药，公司拥有该产品的全球知识产权。KC1036通过...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2620023771?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-18 18:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620023771","market":"sh","top_or_hot":-1,"title":"康辰药业(603590.SH)：KC1036治疗晚期胸腺癌的关键性Ⅲ期临床研究获得CDE批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康辰药业(603590.SH)发布公告，公司自主研发的KC1036片(简称“KC1036”)获得国家药品监督管理局药品审评中心(以下简称“CDE”)批准开展“评估KC1036对比研究者选择的化疗单药治疗既往至少一线含铂化疗失败的晚期复发或转移性胸腺癌的随机、开放、多中心Ⅲ期临床研究”。KC1036是公司自主研发的化学药品1类创新药，公司拥有该产品的全球知识产权。KC1036通过...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1415516.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康辰药业(603590.SH)：KC1036治疗晚期胸腺癌的关键性Ⅲ期临床研究获得CDE批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康辰药业(603590.SH)：KC1036治疗晚期胸腺癌的关键性Ⅲ期临床研究获得CDE批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-18 18:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1415516.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康辰药业(603590.SH)发布公告，公司自主研发的KC1036片(简称“KC1036”)获得国家药品监督管理局药品审评中心(以下简称“CDE”)批准开展“评估KC1036对比研究者选择的化疗单药治疗既往至少一线含铂化疗失败的晚期复发或转移性胸腺癌的随机、开放、多中心Ⅲ期临床研究”。KC1036是公司自主研发的化学药品1类创新药，公司拥有该产品的全球知识产权。KC1036通过...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1415516.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603590","symbol_name":"康辰药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1415516.html","article_id":"2620023771","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620023771","pubTimestamp":1773831086,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"II期临床研究结果显示，KC1036在晚期复发或转移性胸腺癌中展现突出的抗肿瘤疗效且安全性可控。公司于近日获得CDE批准开展KC1036治疗晚期胸腺癌的关键性Ⅲ期临床研究，这是继三线治疗晚期食管鳞癌Ⅲ期临床研究之后，KC1036第2个获批开展关键性Ⅲ期临床研究的适应症。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603590":"康辰药业","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","CDE":"科尔黛伦矿业","LU1223082196.USD":"施罗德环球黄金A Acc","BK4017":"黄金","BK0239":"医药制造"},"translate_title":"Kangchen Pharmaceutical (603590.SH): CDE approval for the pivotal phase III clinical study of KC1036 in the treatment of advanced thymic cancer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603590":1.5,"CDE":1.5},"content_text":"智通财经APP讯，康辰药业(603590.SH)发布公告，公司自主研发的KC1036片(简称“KC1036”)获得国家药品监督管理局药品审评中心(以下简称“CDE”)批准开展“评估KC1036对比研究者选择的化疗单药治疗既往至少一线含铂化疗失败的晚期复发或转移性胸腺癌的随机、开放、多中心Ⅲ期临床研究”。KC1036是公司自主研发的化学药品1类创新药，公司拥有该产品的全球知识产权。KC1036通过抑制VEGFR2、AXL等多靶点实现抗肿瘤活性。KC1036具有较强的VEGFR血管靶向，抑制肿瘤细胞生长;通过抑制AXL，可以改善宿主的抗肿瘤免疫应答，从而避免肿瘤的免疫逃逸。目前KC1036针对消化系统肿瘤、胸腺肿瘤、儿童尤文肉瘤等多个适应症正在开展临床研究，截至目前，已有超过350例受试者入组KC1036临床研究，现有临床研究结果显示了突出的抗肿瘤活性与安全性。II期临床研究结果显示，KC1036在晚期复发或转移性胸腺癌中展现突出的抗肿瘤疗效且安全性可控。公司于近日获得CDE批准开展KC1036治疗晚期胸腺癌的关键性Ⅲ期临床研究，这是继三线治疗晚期食管鳞癌Ⅲ期临床研究之后，KC1036第2个获批开展关键性Ⅲ期临床研究的适应症。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620023771","isCrawlerRequest":true}